43 completed, 29 recruiting, 19 terminated, 18 active not recruiting. 70 Phase 2, 37 Phase 1, 25 Phase 3, 4 Not applicable, 1 Early Phase 1.
Follow abiraterone: new trials by email Literature Review of abiraterone trials Research Report on abiraterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs（apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) Saruparib, Placebo, Enzalutamide - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | AstraZeneca | 1330 | 2026-09-15 | 2026-10-15 |
| Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer | Phase 2 | Recruiting | University of Nebraska | 140 | 2026-09-01 | 2026-10-19 |
| A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone - Neoplasms, Prostate | Phase 3 | Recruiting | GlaxoSmithKline | 684 | 2026-09-01 | 2026-10-02 |
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-10-16 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer INR731, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 208 | 2026-05-25 | 2026-10-23 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer Inavolisib, Enzalutamide, Abiraterone - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Hoffmann-La Roche | 100 | 2026-03-11 | 2026-10-08 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-09-29 |
| A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet - Prostate Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 218 | 2025-12-08 | 2026-03-03 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 123 | 2025-12-05 | 2026-10-15 |
| Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) Abiraterone 250 mg with food + prednisone - Prostate Cancer (Diagnosis) | Phase 2 | Recruiting | SMED Clinical Research | 60 | 2025-12-01 | 2025-12-23 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer Xaluritamig, Darolutamide, Abiraterone - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 1 | Recruiting | Amgen | 60 | 2025-10-07 | 2026-07-02 |
| A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics Abiraterone + ADT - Metastatic Hormone-Sensitive Prostate Cance | Not yet recruiting | Anhui Medical University | 396 | 2025-09-01 | 2025-09-04 | |
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer Abivertinib, Abiraterone - Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Suspended | Sorrento Therapeutics, Inc. | 100 | 2025-09-01 | 2024-03-18 |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 700 | 2025-08-06 | 2026-10-14 |
| Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients Local treatment, Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). - Prostate Cancer Metastatic Disease | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 192 | 2025-08-01 | 2026-03-25 |
Showing 20 of 129. Sign in to see all of them.
Prostatic Neoplasms (88) · Neoplasm Metastasis (11) · Neoplasms (6) · Prostatic Neoplasms, Castration-Resistant (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Urogenital Neoplasms (3) · Bites and Stings (2) · Breast Neoplasms (2) · Bulbo-Spinal Atrophy, X-Linked (2) · Carcinoma, Hepatocellular (2) · Genital Neoplasms, Male (2) · Lymphoma, Non-Hodgkin (2) · Melanoma (2) · Multiple Myeloma (2)
Novartis Pharmaceuticals (6) · AstraZeneca (5) · Amgen (4) · Exelixis (4) · Dana-Farber Cancer Institute (3) · GlaxoSmithKline (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Janssen Research & Development, LLC (3) · Pfizer (3) · Anhui Medical University (2) · Bayer (2) · Celgene (2) · Changhai Hospital (2) · Hoffmann-La Roche (2) · Masonic Cancer Center, University of Minnesota (2)
United States (88) · Australia (29) · Spain (29) · Canada (26) · United Kingdom (26) · France (24) · China (22) · Italy (21) · South Korea (18) · Japan (17) · Brazil (15) · Germany (15) · Belgium (14) · Poland (13) · Taiwan (13)
Jingsong Zhang, MD, PhD (2) · Zachery Reichert, MD, PhD (2) · Abhishek Solanki, MD MS (1) · Albert Font, MD (1) · Alexandra Sokolova (1) · Alison Tree, FRCR (1)
PMID 18309951, PMID 18990168, PMID 22452894, PMID 22747660, PMID 25320340, PMID 25425730, PMID 26718929, PMID 26719232, PMID 27068431, PMID 28178640, PMID 28300506, PMID 28578639, PMID 29384722, PMID 29529169, PMID 29723398, PMID 29740894, PMID 30028657, PMID 30355464, PMID 30686756, PMID 30738780, PMID 30935383, PMID 31122212, PMID 31527168, PMID 31560068, PMID 31823152, PMID 32404868, PMID 32586393, PMID 32994091, PMID 33270906, PMID 33599706, PMID 33836265, PMID 34246347, PMID 34636627, PMID 34646387, PMID 34655838, PMID 34757812, PMID 34903471, PMID 34953525, PMID 35034502, PMID 35317973, PMID 35671327, PMID 36055231, PMID 36059000, PMID 36063830, PMID 36099670, PMID 36210487, PMID 36305957, PMID 36358643, PMID 36572571, PMID 36697317
2025 (4), 2016 (2), 2017 (2), 2004 (1), 2019 (1), 2023 (1), I01CX002277 (1), P01CA203628 (1), P30CA060553 (1), P30CA072720 (1), P30CA093373 (1), P30CA138292 (1), R01CA286127 (1), R01CA300454 (1), U10CA031946 (1)